Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance

Ming-Ling Chang1,2,*, Yung-Kuan Tsou1, Tsung-Hui Hu3, Cheng-Hui Lin1, Wey-Ran Lin1, Chang-Mu Sung1, Tsung-Hsing Chen1, Mei-Ling Cheng4, Kuo-Chin Chang3, Cheng-Tang Chiu1, Chau-Ting Yeh1, Jong-Hwei Su Pang5, Ming-Shi Shiao4

1 Liver Research Center, Division of Hepatology, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 2 Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan, Taiwan, 3 Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 4 Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan

Abstract

Background: The hepatitis C virus (HCV) genotype-specific impacts on the host metabolic alterations remained inconclusive.

Methods: A prospective study including 229 (118 genotype 1 (G1) and 111 G2) consecutive chronic HCV patients who had completed a course of anti-HCV treatment and underwent pre- and 24 weeks post-treatment surveys of metabolic profiles was conducted. Patients were stratified according to the therapeutic response, viral genotype and baseline insulin resistance (IR: homeostasis model assessments of IR (HOMA-IR) ≥2.5). Paired t-tests were used to compare the pre- and post-treatment variables.

Results: Significant post-therapeutic increases in cholesterol, triglyceride, HDL, LDL, apolipoprotein A1 and apolipoprotein B were observed in patients with sustained virological response (SVR) but not in those without. Among those with SVR, post-therapeutic increases in HDL ($p<0.001$) and apolipoprotein A1 ($p=0.012$) were only found in G2, whereas increased triglyceride/HDL ($p=0.01$) ratios were only found in G1 patients. When stratified by baseline IR among those with SVR, a significant increase in post-treatment HDL ($p=0.019$) and apolipoprotein A1 ($p=0.012$) but a decrease in HOMA-IR ($p=0.04$), C-peptide ($p=0.019$) and hemoglobin A1c ($p=0.047$) were found in patients with baseline IR; a significant increase in HOMA-IR ($p=0.002$) was found in patients without baseline IR. The latter change was observed only in G1 ($p=0.01$) but not G2 patients. Although the pre-treatment metabolic profiles of G1 and G2 patients were indifferent, G1 had higher post-treatment triglyceride/HDL ratios ($p=0.041$) and triglyceride ($p=0.044$) levels than G2 patients.

Conclusions: G2 benefit more than G1 patients from viral clearance in metabolic alterations, particularly in those without baseline IR.

Introduction

The hepatitis C virus (HCV) is a human pathogen responsible for acute and chronic liver disease, infecting an estimated 130–170 million individuals worldwide [1]. Its variants are classified into six genotypes [2]. In addition to cirrhosis and hepatocellular carcinoma, HCV induces several complications, including steatosis, dyslipidemia and insulin resistance (IR) [3,4]. Accordingly, it is now considered to cause metabolic alterations instead of being simply a viral infection. In particular, much of the HCV life cycle including the entry into naive cells, infectivity, RNA replication, viral assembly and viral secretion closely associated with lipid metabolism [1,5]. The combination of pegylated interferon (Peg-IFN)-α plus ribavirin has provided a ‘cure’ for a considerable proportion of patients with chronic hepatitis C (CHC), particularly when most patients have the favorable interleukin-28B (IL-28B) genotype [5]. In addition to increasing the curability of difficult-to-treat cases, one of the current challenges is to determine the

* Email: mlchang8210@gmail.com

Copyright: © 2014 Chang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by grants from the Chang Gung Medical Research Program (CMRPG380353, CMRPG381251, CMRPG381252, CMRPG 380401, CMRPG381741 and XMRPG3A0521), the National Science Council, Taiwan (100-2314-B-182-069-, 101-2314-B-182-083- and 102-2628-B-182 -021 -MY3), and in part by a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp to M.L.C. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Merck Sharp & Dohme Corp.

Competing Interests: The author M.L.C. received funding in the form of a research grant from the Investigator Initiated Studies Program of Merck Sharp & Dohme Corp. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Received March 4, 2014; Accepted July 12, 2014; Published August 14, 2014

Citation: Chang M-L, Tsou Y-K, Hu T-H, Lin C-H, Lin W-R, et al. (2014) Distinct Patterns of the Lipid Alterations between Genotype 1 and 2 Chronic Hepatitis C Patients after Viral Clearance. PLoS ONE 9(8): e104783. doi:10.1371/journal.pone.0104783
reversibility of the metabolic alterations and associated complications after viral clearance.

Several contradictions have been noted concerning HCV-related metabolic alterations. First, most large-scale case-control studies have demonstrated that HCV infection leads to lower total cholesterol (TC) levels [6,7]. In a large series, HCV-associated hypocholesterolemia was shown to be most evident with genotype 3 (G3), intermediate with genotype 1 (G1) and not significant with genotype 2 (G2) [8]. However, a proportional relationship was ever reported between TC and the viral load in G2 patients [9]. The source of the apparent conflicts in genotype-specific hypolipidemia of CHC patients may result from individual bias which can not be eliminated completely from case-control studies. Second, the eradication of HCV was regarded to reduce the incidences of type 2 diabetes in both G1 and G2 patients [10]. However, reduced IR after sustained virological responses (SVRs) was observed in G1 but not in G2 or G3 patients [11]. Furthermore, a recent prospective study enrolled G1, 2, 3 and 4 CHC patients failed to demonstrate any difference between the mean pre- and post-anti-HCV treatment homeostasis model assessments of IR (HOMA-IR) values in patients with SVR [12]. The above inconsistencies may arise from the heterogeneous baseline glucose metabolisms of the hosts. Given the inconclusive genotype-specific impact of HCV infection on IR, how IR affects lipid metabolism in CHC patients remains even more unclear.

Comparing the pre- and post-treatment variables in CHC patients with SVR has provided an excellent opportunity to eliminate the interference caused by individual bias when reviewing the impact of HCV on metabolic alterations [12]. Interferon therapy has been associated with increases in TC and triglyceride (TG) levels [13]. However, the impacts of HCV should not be masked by any interferon effect when comparing patients with and without SVR. How viral genotype and baseline glucose metabolism affect the overall host metabolisms might be elucidated by further stratifying the CHC patients by genotype and baseline IR. Therefore, we sought to address the puzzling observations of HCV-related metabolic alterations by conducting a prospective study analyzing the metabolic profiles of CHC patients before and after anti-HCV therapy.

### Materials and Methods

#### Patients

The study group consisted of subjects ≥18 years old with CHC identified by documented HCV antibody (HCV Ab) positivity and detectable HCV RNA for more than 24 weeks. Subjects with liver cirrhosis (LC), alcoholic liver disease, human immunodeficiency virus (HIV), hepatitis B infection, hemochromatosis, coronary heart disease, malignancy and recipients of solid organ transplants as well as those on lipid-lowering (statin and fibrate), glucose-lowering (metformin, glipizide, long acting basal insulin analogue

### Table 1. Baseline characteristics of the CHC patients before anti-HCV treatment.

|                  | G1 (n = 118) | G2 (n = 111) | Student’s t-test or chi-squared P values |
|------------------|--------------|--------------|----------------------------------------|
| Male (%)         | 70 (63.63%)  | 56 (52.33%)  | 0.475                                  |
| Age (yr)         | 53.1+/−12.6  | 550+/−11.8   | 0.251                                  |
| BMI              | 24.0+/−3.4   | 24.9+/−3.4   | 0.072                                  |
| HCV RNA (millionIU/ml) | 5.1+/−8.3    | 1.5+/−2.3    | <0.001*                                |
| Log HCV RNA (IU/ml) | 6.10+/−0.98  | 5.90+/−0.92  | 0.049*                                 |
| HCV core Ag (fmol/L) | 7643.5+/−6965.2 | 3497.7+/−3879.4 | 0.002*                                 |
| IL-28B rs12979860 CC/CT+TT, n (CC%)) | 103/15 (87.3%) | 104/7 (93.6%) | 0.595                                  |
| ALT (U/L)        | 100.6+/−79.3 | 112.5+/−82.7 | 0.354                                  |
| Fatty liver (%)  | 52 (44%)     | 53 (48%)     | 0.881                                  |
| APRI             | 1.53+/−2.2   | 1.42+/−1.66  | 0.817                                  |
| TG (mg/dL)       | 108.4+/−59.  | 99.9+/−44.8  | 0.259                                  |
| TC (mg/dL)       | 170.5+/−32.0 | 166.9+/−32.2 | 0.417                                  |
| HDL (mg/dL)      | 48.8+/−15.6  | 48.9+/−13.2  | 0.946                                  |
| LDL (mg/dL)      | 103.6+/−40.8 | 100.5+/−26.1 | 0.53                                   |
| TG/HDL           | 2.62+/−2.35  | 2.22+/−1.40  | 0.151                                  |
| Apo A1 (g/L)     | 1.57+/−1.09  | 1.38+/−0.25  | 0.166                                  |
| Apo B (g/L)      | 0.83+/−0.20  | 0.81+/−0.19  | 0.651                                  |
| Glucose (AC) (mg/dL) | 100.8+/−33.0 | 100.7+/−29.9 | 0.990                                  |
| Insulin (IU/mL)  | 14.1+/−22.34 | 10.61+/−10.34 | 0.2                                      |
| C-peptide (mg/mL)| 2.93+/−3.02  | 2.76+/−2.09  | 0.712                                  |
| HbA1c (%)        | 5.90+/−1.02  | 41+/−11      | 0.317                                  |
| HOMA-IR          | 4.25+/−10.33 | 2.67+/−3.01  | 0.19                                   |
| SVR (%)          | 90 (77.5%)   | 100 (91.7%)  | 0.005*                                 |

*Chi-squared test;  
*p<0.05.

doi:10.1371/journal.pone.0104783.t001
and dipeptidyl peptidase-4) or anti-hypertension (calcium channel blocker, β blocker, α1-antagonist, diuretics, angiotensin II receptor antagonist, angiotensin converting enzyme inhibitor and nitroglycerin) medications were excluded. LC was diagnosed by histologic findings or repeated ultrasonographic findings consistent with LC, supplemented with clinical features such as esophageal or gastric varices and thrombocytopenia, as described elsewhere [14]. The nonalcoholic nature of the disease was established by clinical assessment that alcohol consumption was less than 10 g/day for women and 20 g/day for men [15]. Coronary heart disease, malignancy and recipients of solid organ transplants were diagnosed by history and chart review, and further confirmed by specialist while indicated. Diet control and adequate aerobic exercise were recommended for the enrolled patients with glucose or lipid abnormality.

**Study design**

118 G1 and 111 G2 Taiwanese patients with CHC consecutively recruited at a tertiary care center between January 2010 and January 2013 were treated with Peg-IFN-2αb (1.5 μg/kg/week, subcutaneously) (PEG-Intron; Schering-Plough Inc., Kenilworth, NJ, USA) and ribavirin (800–1400 mg/day, in two divided doses), according to the reimburse policy of the Bureau of National Health Insurance (BNHI) of the country with some modification. The G1 and the G2 patients received 48-week and 24-week duration of treatment, respectively. All the recruited patients received at least 80% of total Peg-IFN dose, at least 80% of total ribavirin dose and completed at least 80% of total study duration (80/80/80 adherence) [16]. The patients were evaluated for the presence of HCV RNA at 2 weeks before therapy; at 4, 12 and 24 weeks during therapy; at the end of therapy; and 24 weeks after therapy, according to the BNHI’s guideline. SVR was defined as undetectable HCV RNA levels at 24 weeks after the completion of therapy. Single-nucleotide polymorphism of IL28B (rs12979860) was assessed using genomic DNA isolated from EDTA anticoagulated peripheral blood from the patients, as previously described [17]. The HCV RNA levels were tested using the COBAS Amplicor (ver. 2.0, Roche Diagnostics, Tokyo, Japan). The HCV genotype was determined using the InoLipa method (COBAS AmpliPrep/COBAS TaqMan HCV Test, Roche Diagnostics, Tokyo, Japan). The lipid panels (TG, low-density lipoprotein-cholesterol (LDL), high-density lipoprotein-cholesterol (HDL), TC, apolipoprotein A1 (Apo AI) and apolipoprotein B (Apo B)), glucose profiles (fasting glucose, insulin, C-peptide, glycated hemoglobin and HOMA-IR [(fasting insulin μIU/mL×fasting glucose (mmol/L))/22.5]), aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count and HCV core antigen (Ag) assays (Abbott Labs) were evaluated for all patients 2 weeks before and 24 weeks after therapy. The AST to platelet ratio index (APRI) ((AST/34)×100/(platelet count/10^9/ L)) was used to assess liver fibrosis [18]. Body weight and body mass index (BMI) were also determined during each measure-

**Table 2. Comparison of pre- and post-treatment variables in the CHC patients stratified by therapeutic response.**

|                         | SVR (+) (n=195) | Paired t-test P values | SVR (-) (n=34) | Paired t-test P values |
|-------------------------|-----------------|------------------------|----------------|------------------------|
|                         | Pre-treatment value | Post-treatment value | Pre-treatment value | Post-treatment value |
| **Male (%)**            | 109 (56%)       | 16 (52%)               |                |                        |
| **Age (yr)**            | 53.7±12.4       | 56.9±11.4              |                |                        |
| **BMI**                 | 24.4±3.4        | 24.2±3.4               | 0.65           | 23.9±3.3               |
| **HCV RNA (million IU/ml)** | 2.9±6.5       | 0                      | <0.001*        | 5.8±5.2                |
| **Log HCV RNA (IU/ml)** | 5.94±1.01       | 6.48±0.48              | 6.09±0.70      | 0.168                  |
| **IL-28B rs12979860**   |                |                        |                |                        |
| **CC/CT+TT, n (CC%)**   | 183/11 (93.8%)  | 23/11 (68.75%)         |                |                        |
| **TG (mg/dL)**          | 100.3±45.5      | 119.3±72.8             | <0.001*        | 127.4±85.5             |
| **TC (mg/dL)**          | 167.4±31.5      | 183.0±37.2             | <0.001*        | 179.1±26.9             |
| **HDL (mg/dL)**         | 48.5±13.7       | 50.7±18.8              | 0.006*         | 53.2±16.8              |
| **LDL (mg/dL)**         | 100.3±27.4      | 112.1±32.6             | <0.001*        | 105.3±24.5             |
| **TG/HDL**              | 2.32±1.53       | 2.77±2.58              | 0.006*         | 2.93±3.76              |
| **Apo A1 (g/L)**        | 1.40±0.26       | 1.44±0.25              | 0.006*         | 1.46±0.25              |
| **Apo B (g/L)**         | 0.82±0.19       | 0.86±0.21              | <0.001*        | 0.93±0.26              |
| **Glucose (mg/dL)**     | 99.5±30.2       | 103.8±48.8             | 0.117          | 109.9±40.1             |
| **Insulin (μIU/mL)**    | 11.5±14.7       | 11.26±17.19            | 0.783          | 19.58±30.01            |
| **C-peptide (ng/mL)**   | 2.61±1.92       | 10.75±83.87            | 0.329          | 4.94±5.52              |
| **HbA1c (%) (mmol/mol)**| 5.82±0.91       | 5.70±0.85              | 0.125          | 5.91±0.91              |
| **HOMA-IR**             | 3.14±7.14       | 2.84±4.20              | 0.407          | 5.77±9.83              |

*p<0.05.
doi:10.1371/journal.pone.0104783.t002
ments. IR was defined using a HOMA-IR score ≥2.5 [19]. Abdominal ultrasound studies were performed in every patient before therapy and every 6 months afterward to monitor fatty liver, cirrhosis and tumors.

The primary and secondary objectives

The primary and secondary objectives of the current study were to access the HCV viral genotype-specific impacts on the metabolic alteration of the host and to evaluate the interaction between the glucose and lipid metabolism in the CHC patients, respectively.

Biochemistry

AST(<34 U/L); ALT(<36 U/L); platelet (150–450 × 10⁹/L); fasting glucose (Glu (AC): 70–105 mg/dL); insulin (2–17 µIU/mL); C-peptide (0.9–4.3 ng/mL); glycated hemoglobin (hemoglobin A1c (HbA1c) (4.6–5.6%; 27–38 mmol/mol); lipid profile (TC: <200 mg/dL; TG: <150 mg/dL; HDL: male (M): >40 mg/dL; female (F): >50 mg/dL; LDL: <100 mg/dL); Apo A1 (M: 1.10–1.20 g/L; F: 0.90–1.05 g/L); Apo B (M: 0.55–1.4 g/L; F: 0.55–1.25 g/L); HCV core Ag (≥3.00 (reactive) (mI/mL)); hepatitis B virus surface antigens (Ag); HCV Ab (AxSYM 3.0; Abbott Laboratories, Chicago, IL, USA); HIV Ag/Ab combi test, transferrin saturation (M: 15–50%); F: 12–45%); ferritin (M: 20–290 ng/mL; F: premenopausal 4.3–170 ng/mL; postmenopausal 24–260 ng/mL), and HCV RNA (1.5 × 10⁷–6.9 × 10⁷ IU/mL) were measured in the clinical pathology or liver research laboratories of the hospital using routine automated techniques.

Statistics

All statistical analyses were performed using either the Statistical Product and Service Solutions (SPSS ver. 18.0, SPSS Inc. Chicago, USA), MedCalc (MedCalc ver. 12.4, MedCalc Software corp. Maine, USA) or G-power (web-based ver. 3.1) software. The continuous variables were summarized as the means ± standard deviation (SD), and the categorical variables were summarized as the frequencies and percentages. The study size was determined according to reported differences in pre- and post-treatment paired cholesterol levels (mean: 19.7, SD: 19.2; α = 0.05, power = 0.9) [20] with some modification for potential ethnic and viral genotype biases. Univariate linear regression models were used to assess the relationships between various factors to the pre-treatment profiles. The variables found to be associated with the dependent variables in univariate analyses were included in multivariate regression models. The correlations and interactions between the variables as well as confounding factors were determined using correlation and linear regression tests. For a better clarification, the HCV RNA level was log-transformed while indicated. To compare the different variables in the different groups, the continuous variables were analyzed using Student’s t-test, while the categorical variables were analyzed using a chi-squared or Fisher’s exact test, as appropriate. A paired t-test was used with the same variables before and after therapy in the same individuals. Statistical significance was defined at the 5% level based on a two-tailed test of the null hypothesis.

The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institutional review board of the Chang Gung Memorial Hospital. All
the participants had provided their written informed consent to participate in this study.

Results

Baseline characteristics of the CHC patients and factors affected pre-treatment HCV RNA levels

The baseline characteristics of the CHC patients were listed in Table 1. Total 31 subjects under lipid-lowering (6 subjects), glucose-lowering (12 subjects) or anti-hypertension medications (26 subjects) had been excluded from the study. The pre-treatment HCV RNA and HCV core Ag levels in G1 patients were significantly higher than those of G2 patients, while the SVR rate was higher in the G2 patients relative to the G1 patients. No correlation was found between the HCV core Ag and any of the lipid profile items.

Differences between those with and without SVR: increases in all lipids were noted among the patients with SVR, but not in those without

Increases in the TG, TC, HDL, LDL, Apo AI and Apo B levels were found in patients with SVR but not in those without. The glucose profile levels were not different, regardless of the therapeutic response (Table 2).

Differences between G1 and G2 patients after SVR: G2 patients demonstrated increased HDL and Apo AI levels, whereas G1 patients demonstrated increased TG/HDLD ratios

Among the patients with SVR, only G2 patients displayed increased post-treatment HDL and Apo AI levels. In contrast, G1 patients exhibited increased post-treatment TG/HDLD ratios (Table 3). Neither G1 nor G2 patients had significantly different post-treatment HOMA-IR compared to their pre-treatment levels.

Additionally, G1 patients exhibited significantly higher post-treatment TG levels (134.56±84.46 vs. 108.38±64.45 mg/dL, p = 0.032) and TG/HDLD ratios (3.27±3.11 vs. 2.34±1.95, p = 0.037) than G2 patients.

Differences between those with and without baseline IR after SVR: increases in Apo AI and HDL levels but decreases in HOMA-IR, C-peptide and HbA1c levels were noted in patients with baseline IR, but not in those without

Among those with SVR, patients with baseline IR exhibited increased post-treatment lipid profiles, including the HDL and Apo AI levels (Table 4). However, no reversal of Apo B was observed. Moreover, some glucose profiles, including the levels of HOMA-IR, C-peptide and HbA1c, decreased. In contrast, in patients without baseline IR, Apo B rather than Apo AI levels increased; furthermore, glucose, insulin and HOMA-IR increased after SVR. However, none of the post-treatment glucose profiles reached the criteria for diabetes or IR.

Differences between G1 and G2 patients without baseline IR after SVR: G2 patients demonstrated increased HDL and Apo AI levels, while G1 patients demonstrated increased TG levels, TG/HDLD ratios and HOMA-IR levels

Among the G1 (n = 65) and G2 (n = 67) patients without baseline IR who achieved SVR (Figure 1), G2 patients showed increased HDL and Apo AI levels, while G1 patients exhibited increased TG levels, TG/HDLD ratios and HOMA-IR levels. However, the increased pre-treatment HOMA-IR in G1 patients did not reach the criteria for IR or diabetes. Besides, G1 patients had significantly higher post-treatment TG levels (130.89±73.73 vs. 100.88±51.82 mg/dL, p = 0.044) and TG/HDLD ratios (3.11±2.84, vs. 2.01±1.42, p = 0.041) than G2 patients.

Discussion

The most compelling findings of the current study are as follows: (1) Although the HCV viral clearance in both G1 and G2 patients resulted in increases in most lipid profile items, post-therapeutic increases in HDL and Apo AI levels were found only in G2 patients; increased TG/HDLD ratios were found only in G1 patients. Moreover, after SVR, G2 patients had lower post-treatment TG/HDLD ratios and TG levels than G1 patients. (2) Among the patients without baseline IR, G1 patients had increased post-treatment HOMA-IR levels, in contrast to G2 patients. (3) Among the patients with baseline IR, part of the lipid profile including Apo AI and HDL levels increased and part of glucose profile including HOMA-IR, C-peptide and HbA1c levels decreased significantly after viral clearance.

The prevalences of G1 CHC increased with age, while that of G2 CHC decreased with age [21]. However, in the current and other studies enrolled CHC patients consecutively [22], except pre-treatment HCV RNA, no other baseline characteristics, including age, were different between the G1 and G2 patients. Besides, in white patients with G1 CHC, the favorable IL28B rs12979860 CC genotype is associated with less pronounced disturbances in lipid metabolism [23] and with reduced IR [24]. In the current study, however, over 90% of the CHC patients with SVR had favorable IL-28B genotype regardless of HCV genotype (Table 3). Therefore, host factors were less likely to explain the various metabolic alterations in the G1 and G2 patients after viral clearance. The HCV core Ag is strongly associated with serum lipoviral particles [25]. However, it did not correlate with any of the pre-treatment lipid profile items. Individual variation might account for this discrepancy. This observation highlights the importance of examining the changes in the lipid profiles after SVR in the same individuals.

The current study demonstrates that G2 clearance affected the lipid profile more favorably than clearing G1 HCV did. Apart from TG, LDL, TC, and Apo B, G2 HCV clearance also increased the HDL and Apo AI levels, while G1 viral clearance increased the TG/HDLD ratios (Table 3). After SVR, the G1 patients had higher post-treatment TG levels and TG/HDLD ratios than the G2 CHC patients. These genotype-specific impacts on metabolic profiles were even more evident after eliminating the influence of IR, as G1 but not G2 had increased post-therapeutic TG and HOMA-IR levels (Figure 1). Because high TG, low HDL levels and high TG/HDLD ratios all indicate a metabolic syndrome, a cluster of cardiovascular risk factors due to IR [26,27], the worse metabolic profile after SVR might potentially lead to higher cardiovascular risks in G1 patients, as compared with G2 patients. This distinct pattern of lipid alterations between the G1 and G2 CHC patients after SVR is particularly important in areas like Taiwan, where most HCV infections are either G1 or G2 [21,22]. Although the reversal of hypolipidemia in patients with CHC after SVR has been documented in previous studies [20,28-30], to the best our knowledge, this is the first clinical study to disclose the genotype-specific impacts from G1 and G2 HCV infection on lipid metabolism. During basic research, G2 exhibited a significantly higher HDL binding rate than G1 HCV did [31]. After SVR, the higher levels of “free” HDL relieved from the G2 relative to the
G1 HCV complex may contribute to the increased HDL in the G2 patients. Whether there are any differences in the composition of HDL between the G1 and G2 patients before or after SVR requires further investigations like lipoprotein electrophoresis. Furthermore, significantly different viral load of G1 and G2 HCV might have led to different liver damage and subsequently different lipoprotein metabolism.

Among cases without baseline IR, after SVR, increased HOMA-IR levels were noted but did not reach the threshold for diabetes or IR, possibly indicating negligible biological importance (Table 4). It may arise directly from a less favorable lipid rather than glucose metabolism. In contrast, among patients with baseline IR, not only HOMA-IR, but also C-peptide and HbA1c levels decreased after SVR. It was consistent with previous studies [16,32]. Also, because IR usually decreases Apo AI and HDL levels decreased after SVR. It was compatible with previous studies [16,32]. Also, because IR usually decreases Apo AI and HDL levels decreased after SVR. It was compatible with previous studies [16,32].

Table 4. Comparison of pre- and post-treatment variables in the CHC patients with SVR stratified by baseline IR.

|                               | SVR (G1 and G2) with baseline IR (n=63) | SVR (G1 and G2) without baseline IR (n=132) |
|-------------------------------|-----------------------------------------|---------------------------------------------|
|                               | Pre- treatment value | Post- treatment value | Paired t-test P values | Pre- treatment value | Post- treatment value | Paired t-test P values |
| Male (%)                       | 37 (62.7%)              | 68 (60.1%)              | 0.012*                  | 121/7 (91.66%)              | 60 (45.5%)              | 0.003*                  |
| Age (yr)                       | 54.5+/−12.6             | 52.3+/−12.5             | 0.111                  | 100 (75.4%)              | 94 (71.4%)              | 0.188                  |
| BMI                            | 25.7+/−3.6              | 25.5+/−3.5              | 0.111                  | 112 (84.8%)              | 110 (82.9%)              | 0.22*                  |
| IL-28B rs12979860 CC/CT+TT, n (CC%) | 59/4 (93.6%)            | 121/7 (91.66%)          | 0.004*                  | 121/7 (91.66%)            | 121/7 (91.66%)          | 0.004*                  |
| TG(mg/dL)                      | 106.1+/−45.0            | 130.6+/−85.1            | <0.001*                 | 168.3+/−32.8              | 184.1+/−36.1             | <0.001*                 |
| TC(mg/dL)                      | 166.0+/−29.7            | 182.4+/−40.9            | <0.001*                 | 168.3+/−32.8              | 184.1+/−36.1             | <0.001*                 |
| HDL(mg/dL)                     | 43.8+/−13.2             | 47.0+/−11.6             | <0.019*                 | 51.2+/−13.6              | 52.4+/−14.7              | 0.188                  |
| LDL(mg/dL)                     | 100.5+/−25.5            | 112.3+/−35.9            | <0.002*                 | 100.3+/−28.6              | 112.9+/−31.4             | <0.001*                 |
| TG/HDL                         | 2.7+/−1.8               | 3.2+/−3.0               | 0.135                  | 2.0+/−1.2               | 2.4+/−2.2               | 0.022*                  |
| Apo A1(g/L)                    | 1.26+/−0.26             | 1.37+/−0.23             | 0.012*                 | 1.45+/−0.26              | 1.48+/−0.26             | 0.111                  |
| Apo B (g/L)                    | 0.84+/−0.17             | 0.87+/−0.20             | 0.274                  | 0.80+/−0.19              | 0.88+/−0.23             | <0.001*                 |
| Sugar (mg/dL)                  | 116.3+/−44.6            | 120.1+/−76.5            | 0.601                  | 90.2+/−8.9               | 95.0+/−15.7             | 0.001*                  |
| Insulin (µIU/mL)               | 19.7+/−21.9             | 16.8+/−27.0             | 0.223                  | 6.9+/−2.8               | 8.0+/−4.6               | 0.016*                  |
| C-peptide (ng/mL)              | 3.9+/−2.5               | 3.0+/−1.5               | 0.019*                 | 1.9+/−1.0               | 2.2+/−1.8               | 0.095                  |
| HbA1c (%; mmol/mol)            | 6.2+/−1.3; 44+/−14      | 5.9+/−0.8; 41+/−9       | 0.047*                 | 5.6+/−0.4; 37.5+/−4.5     | 5.6+/−0.5; 37.5+/−5.5   | 0.546                  |
| HOMA-IR                        | 6.2+/−11.7              | 4.6+/−6.7               | 0.04*                  | 1.5+/−0.5               | 1.9+/−1.2               | 0.002*                  |

*p<0.05.

doi:10.1371/journal.pone.0104783.t004

The major limitation of the current study was the lack of biopsies to validate the hepatic steatosis and fibrosis. We used ultrasonographic finding to diagnose hepatic steatosis, which is defined as the presence of hepatic steatosis in ≥5% of hepatocytes [35]. Although ultrasonography has 60–94% sensitivity and 84–95% specificity for detecting hepatic steatosis [36], its sensitivity is reduced when <30% of the liver parenchyma is infiltrated by fat [36]. Thus, ultrasonography might underestimate the prevalence of hepatic steatosis. The real role of steatosis in the genotype-specific impacts might need further verifications using liver biopsy or magnetic resonance spectroscopy [37]. To assess hepatic fibrosis, APRI is a noninvasive alternative to liver biopsies, particularly for HCV infections [18]. Whereas an updated meta-analysis had demonstrated that APRI may be more reliable in detecting severe fibrosis [38]. No difference in the pre-treatment APRI levels were found between the G1 and G2 patients might only explain the minimal role of severe fibrosis in the genotype-specific metabolic alterations. To explore the impact of mild fibrosis, liver biopsy is still demanded.

Despite the favorable lipid profile, HCV infections increase cardiovascular events and associated mortalities in large-scale studies [39,40]. Several population-based cohort studies had shown that anti-HCV treatment is associated with improved the long-term cardiovascular outcomes in the CHC patients [34,41]. However, reversing hypolipidemia after SVR may further the emergence of cardiovascular disease in extreme cases [42]. Whether all CHC patients benefit equally from SVR regarding cardiovascular risk must be determined. The current study demonstrated that G2 patients may benefit more than G1 patients.
from viral clearance in metabolic alterations, particularly in those without baseline IR. Therefore, after SVR, the follow-up protocols used to survey cardiovascular events might be individualized in CHC patients according to their viral genotype and the baseline glucose metabolism, at least within 24 weeks after completion of anti-HCV therapy.

Acknowledgments

We would like to thank Dr. Hua-Chien Chen for valuable discussions and for reviewing our manuscript, Abbott Laboratories for supporting the HCV core Ag ELISA Kit and Miss Ena for generously assisting with the HCV core Ag ELISA experiments.

Author Contributions

Conceived and designed the experiments: MLC. Performed the experiments: MLC. Analyzed the data: MLC CTY MSS YKT THH CHL WRL CMS THC MLC KCC JHSP CTC. Contributed reagents/materials/analysis tools: MLC CTY MSS MLC KCC JHSP. Wrote the paper: MLC CTY MSS.

References

1. Negro F (2010) Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 59: 1279–1287.
2. Simmonds P, Bukh J, Combet C, Delacage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962–73.
3. Syed GH, Amako Y, Siddiqui A (2010) Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab 21: 33–40.
4. Negro F (2006) Insulin resistance and HCV: will new knowledge modify clinical management? J Hepatol 45: 514–9.
5. Huang CF, Yeh ML, Huang JF, Yang JF, Hsieh MY, et al. (2012) Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. Antiviral Res 93: 239–44.
6. Dai CY, Chuang WL, Ho CK, Hsieh MY, Huang JF, et al. (2008) Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J Hepatol 49: 9–16.
7. Jan CF, Chen CJ, Chiu YH, Chen LS, Wu HM, et al. (2006) A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection. Int J Obes (Lond) 30: 794–9.
8. Pratt D, Shiffman ML, Duiyo M, Gane E, Rajender Reddy K, et al. (2006) Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. J Hepatol 44: 679–85.
9. Hsu CS, Liu CH, Liu CJ, Wang CC, Chen CL, et al. (2009) Association of lipid profiles with hepatitis C viral load in chronic hepatitis C patients with genotype 1 or 2 infection. Am J Gastroenterol 104: 598–604.
10. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, et al. (2009) Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49: 739–744.

Figure 1. Comparisons of the pre- and post-treatment variables when using paired t tests. Pre-: pre-treatment; post-: post-treatment; G1 no IR: G1 CHC patients without baseline IR achieved SVR (n = 65); G2 no IR: G2 CHC patients without baseline IR achieved SVR (n = 67). *: p<0.05. doi:10.1371/journal.pone.0104783.g001
11. Thompson AJ, Patel K, Chuang WL, Lawitz EJ, Rodriguez-Torres M, et al. (2012) Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. Gut 61: 128–34.

12. Aghemo A, Prati GM, Rumi MG, Soffidini R, D’Ambrosio R, et al. (2012) Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 56: 1681–7.

13. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, et al. (2005) Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 20: 204–206.

14. Liaw YF, Tai DI, Chu CM, Chen TJ (1988) The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 8: 493–496.

15. Brunt EM, Jamney CG, DiBiase-Glenn AM, Neuchwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467–74.

16. Huang JF, Yu ML, Huang CF, Jao SH, Dai CY, et al. (2012) The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 32: 962–9.

17. Lin CY, Chen JY, Lin TN, Jeng VJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6: e18322.

18. Wai CT, Greenson JK, Fontana RJ, Kaldjian JD, Marrero JA, et al. (2010) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 50: 1030–7.

19. Kociatk P, Chudek J, Olszanecka-Glinianowicz M (2012) Prevalence of metabolic syndrome in patients with chronic type B hepatitis: A prospective study. Hepatology 8: 493–496.

20. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 25: 93–104.

21. Crawton R, Tabara Y, Kohara K, Miki T, Kusunoki T, et al. (2011) Serum microRNA-2231 level correlates with virologic responses to pegylated interferon therapy, LDL cholesterol, and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis 10: 79.

22. Prasad H, Ryan DA, Celzo MF, Stapleton D (2012) Metabolic syndrome: definition and therapeutic implications. Postgrad Med 124: 21–30.

23. Kocełak P, Chudek J, Olszanecka-Glinianowicz M (2012) Prevalence of metabolic syndrome, insulin resistance and serum high molecular adiponectin in Japanese community-dwelling adults. Lipids Health Dis 10: 79.

24. Aghemo A, Prati GM, Rumi MG, Soffidini R, D’Ambrosio R, et al. (2012) Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C. Hepatology 56: 1681–7.

25. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, et al. (2005) Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 20: 204–206.

26. Liaw YF, Tai DI, Chu CM, Chen TJ (1988) The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 8: 493–496.

27. Brunt EM, Jamney CG, DiBiase-Glenn AM, Neuchwander-Tetri BA, Bacon BR (1999) Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467–74.

28. Huang JF, Yu ML, Huang CF, Jao SH, Dai CY, et al. (2012) The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy. Liver Int 32: 962–9.

29. Lin CY, Chen JY, Lin TN, Jeng VJ, Huang CH, et al. (2011) IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 6: e18322.

30. Wai CT, Greenson JK, Fontana RJ, Kaldjian JD, Marrero JA, et al. (2010) A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 50: 1030–7.

31. Kociatk P, Chudek J, Olszanecka-Glinianowicz M (2012) Prevalence of metabolic syndrome and insulin resistance in overweight and obese women according to the different diagnostic criteria. Minerva Endocrinol 37: 247–54.

32. Corey KE, Kane E, Munroe C, Barlow LL, Zheng H, et al. (2009) Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 50: 1030–7.

33. Rashid S, Udellman KD, Lewis GF (2002) The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 16: 24–8.

34. Hsu YC, Lin JT, Ho JJ, Kao YH, Huang YT, et al. (2013) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology Oct 12. doi: 10.1002/hep.26892.

35. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, et al. (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55: 2005–2023.

36. Haner OW, Aigueire DA, Casola G, Lavine JE, Woenckhaus M, et al. (2006) Fatty liver: imaging patterns and pitfalls. Radiographics 26: 1637–1653.

37. Kang GH, Cruijse I, Shihmorteza M, Wollison T, Gami AS, et al. (2011) Reproducibility of MRI-determined proton density fat fraction across two MRI scanner platforms. Acad Reson Imaging 34: 929–34.

38. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XF, et al. (2011) Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 53: 726–36.

39. Guiltinan AM, Kaidaara Z, Castor B, Oland J, Stridlo A, et al. (2008) Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 167: 743–50.

40. Lee MH, Yang HI, Jen CL, Lu SN, Yeh SH, et al. (2011) Community and Personal risk factors for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology Oct 12. doi: 10.1002/hep.26892.

41. Hsu YC, Lin JT, Ho JJ, Kao YH, Huang YT, et al. (2013) Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology Oct 12. doi: 10.1002/hep.26892.

42. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, et al. (2005) Statin therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 20: 415–23.

43. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, et al. (2005) Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352: 29–38.